Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
159 participants
INTERVENTIONAL
2022-12-03
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does The Combined Use Of Local And Intravenous Tranexamic Acid Offer Better Surgical Field Quality During Functional Endoscopic Sinus Surgery? A Placebo-Controlled Clinical Trial
NCT03965767
Nebulized Tranexamic Acid in Sinus Surgery
NCT04905901
Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries
NCT06777966
The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery
NCT00671281
Efficacy of Oral Diltiazem on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery
NCT03580590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Using oral vs. intravenous forms of the drug will add to our knowledge and improve outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
No intervention
No interventions assigned to this group
Oral tranexamic
The participants will receive 4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
Oral tranexamic acid
4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
Intravenous tranexamic
The participants will receive 15 mg/kg in a 20ml syringe slowly tranexamic acid during induction.
Intravenous tranexamic acid
15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral tranexamic acid
4 tablets of tranexamic acid 500mg (equal 2gm) 2 hours before surgery in the ward.
Intravenous tranexamic acid
15mg/kg of tranexamic acid in a 20ml syringe slowly intravenous during induction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: Both sexes.
* Age between 18 and 40 years.
* Patients scheduled for FESS under general anesthesia.
Exclusion Criteria
* History of allergy to the medications used in the study.
* History of venous or arterial thrombosis.
* history of cardiovascular diseases including AF, IHD, or hypertension.
* History of chest problems including pulmonary embolism, bronchial asthma and COPD.
* History of cerebrovascular stroke.
* History of drug or alcohol abuse.
* Taking opioids or sedative medications.
* Hepatic or renal failure.
* Bleeding disorders, antiplatelets (aspirin, clopidogrel) or anticoagulant (warfarin).
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tamer Samir Abdelsalam
Lecturer of Anesthesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine, Ain Shams University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU R 237/ 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.